Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of CG-P5 Peptide Eye Drops in Wet AMD
NCT06132035Phase 1Recruiting
- Sponsor
- Caregen Co., Ltd.
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised trial of CG-P5 peptide in exudative macular degeneration (3 arms), sponsored by Caregen Co., Ltd. Primary endpoints: Percentage of occurrence of Adverse Events at Day 84, Change in Intraocular Pressure at Day 84 and 1 more. Started Dec 2023; status: recruiting.
02
Drugs
CG-P5 peptide
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT06132035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132035.